Indaptus Therapeutics (INDP) Capital Expenditures (2020 - 2021)

Indaptus Therapeutics (INDP) posted quarterly Capital Expenditures of $1654.0 for Q3 2021, up 37.83% quarter-over-quarter from $1200.0 in Q2 2021.

Indaptus Therapeutics (INDP) Capital Expenditures (2020 - 2021) Analysis & Trends

Indaptus Therapeutics' Capital Expenditures history runs 2 years deep, the most recent figure standing at $1654.0 for Q3 2021.

In Q3 2021, Capital Expenditures changed N/A year-over-year to $1654.0; the TTM figure through Dec 2021 stood at $3854.0 (changed N/A YoY), while the FY2021 annual figure was $3854.0, changed N/A from the prior year.
Capital Expenditures for Q3 2021 stood at $1654.0, up from $1200.0 in the prior quarter.
The five-year high for Capital Expenditures was $3000.0 in Q1 2020, with the low at $1000.0 in Q1 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capex (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	112.20 Mn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	240.20 Mn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	-
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	37.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	25.02 Mn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	34.68 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	6.26 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	251.02 Mn
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	-73.57 Mn
10	Indaptus Therapeutics	157.94 Mn	146.38 Mn	-	-

Download Data